Byondis Appoints Timo van den Berg as Senior Director, Immuno-Oncology R&D
NIJMEGEN, Netherlands, July 15, 2021 /PRNewswire/ --Byondis B.V. today announced the appointment of Timo K. van den Berg, Ph.D., as senior director, Immuno-Oncology (IO) Research and Development.
- NIJMEGEN, Netherlands, July 15, 2021 /PRNewswire/ --Byondis B.V. today announced the appointment of Timo K. van den Berg, Ph.D., as senior director, Immuno-Oncology (IO) Research and Development.
- Van den Berg will assume this role on September 1, operating out of Byondis' headquarters in Nijmegen.
- In his new role, Van den Berg will be instrumental in helping shape Byondis' IO pipeline, which includes the anti-SIRP monoclonal antibody BYON4228.
- "I am very excited about this new chapter in my career," said Professor van den Berg.